statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaccine Stocks Erupt After Bird Flu Cases Reported In US & Australia

 Shares of vaccine companies surged on Wednesday following two reports of human bird flu infections, one in the US and...

Vaccine Stocks Erupt After Bird Flu Cases Reported In US & Australia

CureVac (NASDAQ:CVAC - Get Free Report)s stock had its "neutral" rating reaffirmed by Guggenheim in a research report issued on Friday, Benzinga reports.
CureVac Trading Up 3.4 %
NASDAQ CVAC...

Guggenheim Reiterates "Neutral" Rating for CureVac (NASDAQ:CVAC)

CureVac posts early efficacy results for GSK-partnered flu shot...

CureVac posts early efficacy results for GSK-partnered flu shot

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CureVac announces Phase 2 interim data from influenza vaccine program

Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strainsFor influenza A strains, geometric mean titers numerically exceeded those elicited by...

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Curevac N.V. (CVAC) has released an update. CureVac N.V., in partnership with GSK, reports encouraging interim results from their Phase 2 study on...

CureVac's Influenza Vaccine Shows Strong Phase 2 Results

For the last three days, A.I.dvisor has detected that CVAC's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

CureVac (CVAC, $3.03) Aroon Indicator entered a Downtrend on March 28, 2024.

Shares of CureVac (NASDAQ:CVAC  Get Free Report) shot up 4.3% on Thursday . The stock traded as high as $3.19 and last traded at $3.18. 59,868 shares traded hands during trading, a decline of...

CureVac (NASDAQ:CVAC) Trading 4.3% Higher

CureVac (CVAC, $3.05) Aroon Indicator entered a Downtrend on March 27, 2024.

Shares of CureVac (NASDAQ:CVAC  Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $2.94, but opened at $2.81. CureVac shares last traded...

CureVac (NASDAQ:CVAC) Shares Gap Down to $2.94

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Watchers	6,478
52-Wk Low	$2.22
52-Wk High	$12.36

Volume	834,425.00
52-Wk High	$12.36
52-Wk Low	$2.22

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.26	--	--	N/A
Q1'24	-$0.29	--	--	N/A
Q4'23	-$0.26	--	--	N/A
Q3'23	-$0.24	--	--	N/A
Q2'23	-$0.26	--	--	N/A

CVAC CureVac N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals